{"id":"doxorubicin-hydrochloride-liposome-injection-carboplatin","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":"50-70","effect":"Nausea and vomiting"},{"rate":"40-60","effect":"Alopecia"},{"rate":"20-40","effect":"Mucositis"},{"rate":"5-15","effect":"Cardiotoxicity (reduced with liposomal formulation)"},{"rate":"10-20","effect":"Nephrotoxicity"},{"rate":"10-30","effect":"Peripheral neuropathy"}]},"_chembl":{"chemblId":"CHEMBL1351","moleculeType":"Small molecule","molecularWeight":"371.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Doxorubicin hydrochloride liposome is an anthracycline that intercalates into DNA and inhibits topoisomerase II, preventing DNA unwinding and triggering cell death. Carboplatin is a platinum-based alkylating agent that forms intra- and inter-strand DNA cross-links, blocking replication and transcription. The liposomal formulation enhances doxorubicin delivery to tumors while reducing cardiotoxicity. Together, these agents provide synergistic cytotoxic effects against rapidly dividing cancer cells.","oneSentence":"Doxorubicin liposome intercalates DNA to inhibit topoisomerase II while carboplatin forms DNA cross-links, together inducing apoptosis in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:55.301Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ovarian cancer"},{"name":"Breast cancer"},{"name":"Other solid tumors (under investigation in phase 3)"}]},"trialDetails":[{"nctId":"NCT07078604","phase":"PHASE2","title":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-11","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":20},{"nctId":"NCT06840002","phase":"PHASE1, PHASE2","title":"A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-03-18","conditions":"Ovarian Cancer","enrollment":150},{"nctId":"NCT05159193","phase":"PHASE3","title":"Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-12-20","conditions":"Breast Cancer","enrollment":372},{"nctId":"NCT03794778","phase":"PHASE4","title":"Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer","status":"UNKNOWN","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2019-03-19","conditions":"Efficacy and Safety","enrollment":396},{"nctId":"NCT04337632","phase":"PHASE3","title":"Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer","status":"UNKNOWN","sponsor":"Hunan Cancer Hospital","startDate":"2017-08-01","conditions":"Ovarian Cancer","enrollment":338},{"nctId":"NCT01593228","phase":"PHASE3","title":"Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-05","conditions":"Solid Tumors","enrollment":37},{"nctId":"NCT00102973","phase":"PHASE3","title":"TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer","status":"COMPLETED","sponsor":"Telik","startDate":"2004-12","conditions":"Ovarian Neoplasms","enrollment":244},{"nctId":"NCT01204996","phase":"PHASE1","title":"A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2010-05","conditions":"Cancer","enrollment":53}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PP"],"phase":"phase_3","status":"active","brandName":"Doxorubicin Hydrochloride Liposome Injection+carboplatin","genericName":"Doxorubicin Hydrochloride Liposome Injection+carboplatin","companyName":"Hunan Cancer Hospital","companyId":"hunan-cancer-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Doxorubicin liposome intercalates DNA to inhibit topoisomerase II while carboplatin forms DNA cross-links, together inducing apoptosis in cancer cells. Used for Ovarian cancer, Breast cancer, Other solid tumors (under investigation in phase 3).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}